OP0232 Female gender and positive rheumatoid factor predict low serum infliximab levels and positive anti-drug antibodies, which associate with treatment failure on infliximab in patients with early rheumatoid arthritis. report from the swefot trial population

Abstract

BackgroundTumour necrosis factor (TNF) inhibitors, with infliximab (IFX) first on the market, have revolutionised treatment of patients with rheumatoid arthritis (RA). However, in a substantial proportion of patients, they lose...